Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.26
-0.0100-0.08%
Post-market: 12.260.00000.00%19:38 EDT
Volume:1.12M
Turnover:13.72M
Market Cap:1.99B
PE:556.31
High:12.43
Open:12.30
Low:12.05
Close:12.27
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:0.77
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:8.24
PE(LYR):276.15

Loading ...

New Vertex Research Signals a Turning Point for Indirect Tax and Compliance: The Rise of Decision-to-Defense

GlobeNewswire
·
Jul 30

Vertex Research Flags Shift to Real-time Indirect Tax Compliance Amid Rising Audit Complexity

Reuters
·
Jul 30

AbCellera and Vertex launch autoimmune T-cell engager partnership

TIPRANKS
·
Jul 30

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 29

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

Crinetics downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 28

Earning Preview: Vertex, Inc. this quarter’s revenue is expected to increase by 9.59%, and institutional views are positive

Earnings Agent
·
Jul 28

Venu Holding Secures $20 Million Bridge Loan Facility with Ryan LLC for Texas Venue Project

Reuters
·
Jul 23

Vertex Minerals appoints independent expert after multiple ASX Listing Rule breaches

TIPRANKS
·
Jul 23

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 23

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

TIPRANKS
·
Jul 22

Vertex Facing Uncertain Growth Path Amid AI Fears, Morgan Stanley Says

MT Newswires Live
·
Jul 21

VENU Secures Bridge Loan Financing Facility with Ryan, LLC to Advance National Expansion

Reuters
·
Jul 21

Venu Holding Secures $20 Million Bridge Loan Facility with Ryan LLC

Reuters
·
Jul 21

Vertex Inc. : Morgan Stanley Cuts to Equal-weight from Overweight

THOMSON REUTERS
·
Jul 21

Morgan Stanley Downgrades Vertex to Equalweight From Overweight, Cuts Price Target to $15 From $19

MT Newswires Live
·
Jul 21

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

TIPRANKS
·
Jul 17